# Blood Screening Market

> Blood Screening Market Research Report By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) - Forecast till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 9.0%
- **2026:** USD 3.77 Billion
- **2035:** USD 8.19 Billion
- **Key Players:** Grifols S.A., F. Hoffmann-La Roche AG, Abbott Laboratories, Bio-Rad Laboratories, Ortho Clinical Diagnostics, Immucor (Werfen), Hologic Inc., Quotient Limited

**Report ID:** MRFR/MED/5434-HCR · **Pages:** 85 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 08, 2026

**URL:** https://www.marketresearchfuture.com/reports/blood-screening-market-6899

---

## Market Summary

## Blood Screening Market Summary

The Blood Screening Market size was valued at USD 3.46 Billion in 2025, and the market is projected to grow from USD 3.77 Billion in 2026 to USD 8.19 Billion by 2035, registering a CAGR of 9.0% during the forecast period 2026–2035. This expansion is anchored in tightening regulatory mandates that now prioritize individual donor risk assessment over blanket deferral policies, a shift that compels blood centers worldwide to upgrade testing infrastructure. The WHO's Action Framework for Blood Safety 2024–2030 has accelerated adoption of integrated screening platforms across low- and middle-income countries, channeling an estimated USD 1.2 Billion in multilateral funding toward pathogen detection modernization [[1]](https://who.int).

A technology transformation is reshaping how blood products are tested before release. Legacy serological assays — once the backbone of donor screening — are giving way to multiplex molecular platforms capable of detecting HIV, HBV, HCV, and emerging pathogens in a single run. The U.S. FDA's 2024 guidance on pathogen-reduction technology interoperability has pushed manufacturers to develop systems that pair screening with inactivation, reducing the overall window period for transfusion risk [[2]](https://fda.gov). Automation rates at large blood centers now exceed 85% in North America and Western Europe, up from roughly 60% a decade ago.

North America commands approximately 38% of the global Blood Screening Market, driven by stringent AABB standards and robust voluntary donation infrastructure. Asia-Pacific stands as the fastest-growing region with a projected CAGR of 10.7%, propelled by government-led centralization of blood banking in India and China. Europe holds the second-largest share at around 27%, underpinned by the EU Blood Directive revisions requiring expanded pathogen panels [[3]](https://ec.europa.eu). The Blood Screening Market is poised for sustained double-digit regional gains as universal screening mandates extend across sub-Saharan Africa and Southeast Asia.

## Key Report Takeaways

### • By Product

- Reagents and kits captured roughly 51% of the Blood Screening Market in 2025, reflecting high consumable intensity in routine donor testing.
- Instruments are projected to register the fastest segment CAGR of 10.6% through 2035, as blood centers replace aging analyzers with fully automated platforms.

### • By Technology

- [Nucleic acid amplification testing](https://www.marketresearchfuture.com/reports/nucleic-acid-amplification-testing-market-43133) (NAT) accounted for approximately 45% of revenue in 2025.
- Next-generation sequencing is forecast to advance at an 11.9% CAGR through 2035, driven by its ability to identify novel or variant pathogens.

### • By Screening Target

- Infectious disease panels dominated the Blood Screening Market with around a 53% share in 2025.

### • By End-User

- Blood banks represented approximately 63% of end-user demand in 2025.
- Clinical laboratories are expected to post the highest end-user CAGR of 11.0% through 2035.

### • By Region

- North America led the Blood Screening Market with a 38% share in 2025.
- Asia-Pacific is projected to grow at a 10.7% CAGR through 2035, outpacing all other regions.

## Market Size and Forecast (2021–2035)

Market Research Future employs a triangulated approach combining primary interviews with blood bank directors, procurement data from hospital group-purchasing organizations, and regulatory filings from the FDA, EMA, and national health authorities. Historical figures (2021–2024) reflect actual reported revenues; the base year (2025) is estimated from trailing-twelve-month company disclosures; and the forecast period (2026–2035) applies a calibrated compound growth rate of 9.0%.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Regulatory mandates for individual donor risk assessment | ~18% | Global | Short-term (≤2 yr) | [2] |
| Automation and integrated screening platforms | ~16% | North America, Europe | Medium-term (2–4 yr) | [8] |
| Rising global blood donation volumes | ~14% | Asia-Pacific, Africa | Long-term (≥4 yr) | [1] |
| Multiplex NAT panel expansion | ~13% | North America, Europe | Short-term (≤2 yr) | [9] |
| Pathogen-reduction technology integration | ~12% | Europe, Asia-Pacific | Medium-term (2–4 yr) | [10] |
| Point-of-care molecular platforms | ~10% | Emerging markets | Long-term (≥4 yr) | [11] |
| AI-driven inventory and release algorithms | ~8% | North America, Japan | Medium-term (2–4 yr) | [12] |

### Regulatory Mandates for Individual Donor Risk Assessment

The U.S. donor pool was altered by the FDA's 2023 final guidance, which substituted individualized risk-based questions for blanket MSM deferral, adding a projected 3–5% more eligible donors each year [[2]](https://fda.gov). The market for addressable reagents and instruments will directly grow as a result of this policy change, which calls for more thorough screening of each donation unit. Similar changes in Australia and the UK (FAIR policy, 2022) have sparked a coordinated global movement toward behavioral-risk questionnaires combined with improved molecular testing, guaranteeing that the blood screening market will be able to meet the growing demand from both increased donor volumes and more stringent testing procedures per unit.

### Automation and Integrated Screening Platforms

Semi-automated operations are being replaced by fully integrated platforms that incorporate sample loading, NAT amplification, and result interpretation in a closed system in large-volume blood centers that process more than 500,000 donations annually. Labor expenses are now reduced by about 30% thanks to Grifols' Panther system and Roche's Cobas 6800/8800, which can manage throughput surpassing 1,000 samples per eight-hour shift [[8]](https://diagnostics.roche.com). There will be a focused wave of instrument procurement for the blood screening market between 2026 and 2030 as the capital investment cycle, which is normally a 7–10 year replacement window, enters a major refresh phase across North American and European centers.

### Rising Global Blood Donation Volumes

WHO data indicates that global [blood collection](https://www.marketresearchfuture.com/reports/blood-collection-market-7013) reached 118 million units in 2023, up from 108 million in 2018, with low- and middle-income countries accounting for the majority of incremental growth [[1]](https://who.int). India's National Blood Transfusion Council targets a 25% increase in voluntary donations by 2028 through mobile collection camps in tier-2 and tier-3 cities [[6]](https://mohfw.gov.in). Each additional donation unit requires a full screening panel, directly translating collection volume gains into reagent consumption growth for the Blood Screening Market.

### Multiplex NAT Panel Expansion

The evolution from single-analyte to multiplex NAT panels — now covering HIV-1/2, HBV, HCV, and increasingly Zika, Babesia, and West Nile Virus in a single cartridge — raises the revenue per test while reducing turnaround time [[9]](https://doi.org/10.1111/vox.13400). The FDA's 2024 approval of expanded Babesia screening nationwide (previously limited to endemic states) added an entirely new line item to the U.S. Blood Screening Market, estimated at USD 120 Million in annual incremental reagent spend across the American Red Cross and Vitalant networks.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High upfront capital costs for integrated platforms | ~–6% | Emerging markets | Medium-term (2–4 yr) | [13] |
| Evolving LDT regulatory compliance burden | ~–5% | United States | Short-term (≤2 yr) | [14] |
| Declining paid-donor models reducing testing volumes | ~–4% | South America, parts of Asia | Long-term (≥4 yr) | [1] |
| Supply chain concentration for critical reagents | ~–3% | Global | Short-term (≤2 yr) | [15] |
| Reimbursement pressure on per-unit test costs | ~–3% | Europe | Medium-term (2–4 yr) | [16] |

### High Upfront Capital Costs for Integrated Platforms

Many regional blood centers in sub-Saharan Africa and Southeast Asia cannot afford these systems since a fully automated screening line, comprising instruments, IT middleware, and verified reagent contracts, can cost more than USD 2.5 million per installation [[13]](https://worldbank.org). Reagent-rental methods reduce capital barriers to some extent, but they also bind facilities to long-term supply contracts that restrict competitive switching and potentially raise test costs over the course of the contract, which hinders the wider penetration of the blood screening market in price-sensitive areas.

### Evolving LDT Regulatory Compliance Burden

The FDA's 2024 proposed rule to bring laboratory-developed tests under formal premarket review has introduced significant compliance uncertainty for hospital-based and reference laboratories that developed proprietary screening assays [[14]](https://federalregister.gov). Estimated compliance costs of USD 30,000–50,000 per assay per year could push smaller labs toward commercial kit adoption — a net positive for kit manufacturers but a near-term drag on testing volumes as labs pause development pipelines and reassess their screening menus.

### Supply Chain Concentration for Critical Reagents

Three production facilities in the US and Switzerland provide more than 70% of the world's supply of specific lyophilized NAT reagent components [[15]](https://bnef.com). A single-site outage can result in 8–12 week backorders, forcing blood facilities to switch to less sensitive immunoassay backup techniques, as the COVID-era interruptions showed. Procurement trust in the blood screening market is still hampered by this concentration risk, especially among national health systems that require continuous testing capabilities.

## Opportunities

## Blood Screening Market Opportunities

### Point-of-Care Molecular Screening for Remote Collection Sites

Mobile blood drives in rural areas across India, Nigeria, and Indonesia currently rely on rapid immunochromatographic tests that offer lower sensitivity than centralized NAT [[11]](https://path.org). The emergence of cartridge-based, battery-operated molecular platforms — such as those adapted from GeneXpert's tuberculosis architecture — could enable near-patient NAT-equivalent screening at collection points. This would unlock an estimated 15–20 million additional safe donation units annually, significantly expanding the addressable Blood Screening Market in regions where cold-chain logistics currently limit centralized testing.

### AI-Powered Predictive Inventory and Release Systems

Blood centers managing perishable inventories (red cells have a 42-day shelf life) are investing in machine-learning algorithms that predict demand by blood type, season, and trauma incidence [[12]](https://doi.org/10.1016/j.tmrv.2024.01.003). These systems integrate screening turnaround data to optimize release timing, reducing wastage rates from the current 5–8% benchmark to below 3%. As algorithms require real-time integration with screening platforms, they create a new software-services revenue layer adjacent to the traditional Blood Screening Market instrument-and-reagent model.

### Pathogen-Reduction as a Screening Complement

Pathogen-reduction technologies (PRT) — which use UV light or chemical agents to inactivate residual pathogens in plasma and platelets — are gaining traction as a complementary layer to conventional screening [[10]](https://cerus.com). While PRT does not replace infectious-disease testing, it enables streamlined panel decisions for platelet concentrates. European adoption of Cerus' Intercept system across France and Belgium has already altered procurement dynamics, creating integration opportunities for screening vendors who can co-package testing and inactivation workflows.

### Expansion into Emerging-Market National Blood Programs

Sub-Saharan Africa processes approximately 8 million donation units annually but screens fewer than 60% with WHO-recommended testing protocols [[1]](https://who.int). The African Union's Agenda 2063 health targets and PEPFAR's continued HIV testing mandates are converging to create procurement pipelines worth an estimated USD 300–400 Million through 2030 for the Blood Screening Market. Manufacturers that establish local reagent distribution and cold-chain infrastructure stand to capture first-mover advantages in these high-growth, underserved corridors.

### Data Monetization Through Epidemiological Surveillance Platforms

Screening data from millions of donor samples per year represents a rich epidemiological dataset for public-health surveillance. Companies that offer anonymized, aggregated pathogen-prevalence dashboards — layered onto existing screening contracts — can unlock subscription-based revenue streams from national health agencies and research institutions. The CDC's collaboration with blood-center networks on Zika and SARS-CoV-2 seroprevalence demonstrated the commercial and public-health value of this data layer.

## Future Outlook

## Blood Screening Market Future Outlook

### AI and Machine-Learning Integration in Screening Workflows

Artificial intelligence will move beyond inventory optimization into active screening-result interpretation by 2028–2030. Deep-learning algorithms trained on millions of donor-sample results are demonstrating the ability to flag indeterminate NAT signals with 95%+ concordance to expert manual review, potentially reducing confirmatory testing turnaround from 48 hours to under 6 hours [[12]](https://doi.org/10.1016/j.tmrv.2024.01.003). For the Blood Screening Market, this translates into faster product release, lower discard rates, and a new software-licensing revenue model layered atop existing instrument placements.

### Next-Generation Sequencing for Variant Surveillance

NGS-based metagenomic screening — capable of detecting any pathogen without a priori knowledge of the target — is expected to transition from research-use-only to clinical deployment between 2030 and 2033 [[7]](https://doi.org/10.1111/trf.17250). The technology addresses a critical gap: conventional NAT panels are blind to novel or engineered pathogens. WHO's International Blood Safety Working Group has identified metagenomic surveillance as a strategic priority, and early pilots at the New York Blood Center and Sanquin (Netherlands) are generating performance data that regulators will use to frame approval pathways for the Blood Screening Market.

### Sustainability and Green Blood-Banking Practices

Environmental sustainability is entering the blood-banking agenda as healthcare systems face decarbonization targets. Single-use plastics from screening consumables — estimated at 12,000 metric tons annually across global blood centers — are drawing scrutiny [[19]](https://practicegreenhealth.org). Manufacturers developing recyclable cartridge housings and reduced-reagent-volume platforms will gain procurement preference under emerging EU green public procurement criteria. The Blood Screening Market will increasingly reward companies that can demonstrate lifecycle carbon-footprint reductions alongside diagnostic performance.

### Decentralized and Mobile Screening Architectures

The traditional hub-and-spoke model, where collected units are shipped to a central lab for screening, is being challenged by portable molecular platforms that bring NAT-equivalent testing to the collection point. By 2035, an estimated 20–25% of screening in low-resource settings could occur at mobile or satellite sites rather than centralized laboratories [[11]](https://path.org). This architectural shift will restructure the competitive landscape of the Blood Screening Market, favoring companies that offer compact, connectivity-enabled, and cold-chain-independent solutions over those optimized solely for high-throughput centralized operations.

## Segment Insights

## Blood Screening Market Segmentation

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Reagents and Kits | 51% share (2025) | High consumable intensity per donation unit |
| Instruments | 10.6% CAGR (2026–2035) | Automation refresh cycle at large blood centers |
| Software and Services | USD 0.21 Billion (2025) | LIMS integration and data-analytics adoption |

Reagents and kits remain the revenue backbone of the Blood Screening Market, reflecting the consumable-driven business model where each of the estimated 120 million global donation units requires a full panel of NAT and immunoassay reagents. Closed-system reagent contracts — where instrument placement is tied to exclusive reagent purchase — ensure high recurring revenue for manufacturers like Grifols, Roche, and Abbott.

The instruments segment is gaining momentum as blood centers enter a synchronized replacement cycle. Systems installed during the 2012–2016 NAT adoption wave are now approaching end-of-life, creating a concentrated procurement window. Next-generation platforms emphasize walk-away automation, reduced sample-volume requirements, and built-in connectivity for real-time result reporting to national hemovigilance databases.

### By Technology

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Nucleic Acid Amplification Testing (NAT) | 45% share (2025) | Regulatory mandate for molecular-level pathogen detection |
| Immunoassay | USD 0.92 Billion (2025) | Cost-effective high-volume serology screening |
| Rapid Tests | 7.8% CAGR (2026–2035) | Point-of-collection use in low-resource settings |
| Next-Generation Sequencing | 11.9% CAGR (2026–2035) | Emerging-pathogen surveillance and variant detection |

NAT dominates the technology landscape of the Blood Screening Market because regulatory agencies in over 80 countries now require molecular testing for HIV and hepatitis viruses in donated blood. The technology's ability to detect viral nucleic acids during the pre-seroconversion window period — typically 5–10 days for HIV and 20–25 days for HCV — makes it indispensable for closing the residual-risk gap that immunoassays alone cannot address.

Immunoassay platforms continue to serve a complementary role, particularly for blood-group serology and confirmatory antibody testing. Rapid tests, while limited in sensitivity, remain the primary screening modality in countries where centralized NAT infrastructure has not yet been established, serving an essential function in approximately 40 WHO member states across Africa and Southeast Asia.

### By Screening Target

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Infectious Disease Panels | 53% share (2025) | Mandatory HIV, HBV, HCV screening across all jurisdictions |
| Blood Group Typing | USD 0.72 Billion (2025) | Pre-transfusion compatibility and Rh-D determination |
| Other Screening Targets | 9.4% CAGR (2026–2035) | Sickle-cell trait, CMV, malaria parasite detection |

Infectious disease panels represent the largest screening-target category in the Blood Screening Market, driven by universal regulatory requirements for HIV, HBV, and HCV testing across virtually every jurisdiction with an organized blood supply. Panel scope continues to expand — Babesia, hepatitis E, and dengue are the most recently added analytes in developed markets, while Chagas disease testing remains mandatory throughout Latin America.

### By End-User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Blood Banks | 63% share (2025) | Centralized high-volume donor screening operations |
| Hospitals | USD 0.48 Billion (2025) | In-house transfusion services and emergency screening |
| Clinical Laboratories | 11.0% CAGR (2026–2035) | Reference testing and confirmatory assay demand |

Blood banks — including national blood services, Red Cross/Red Crescent societies, and independent community blood centers — process the vast majority of donations and therefore represent the dominant end-user segment in the Blood Screening Market. Their procurement patterns are characterized by long-term reagent-rental contracts, centralized tender processes, and high sensitivity to per-test cost optimization.

Clinical laboratories are the fastest-growing end-user segment as reference labs expand their transfusion-medicine testing portfolios and hospital systems increasingly outsource confirmatory and supplemental testing to specialized facilities.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 38% share (2025) | Automation refresh cycle; expanded Babesia/bacteria panels |
| Europe | 27% share (2025) | EU Blood Directive compliance; PRT integration |
| Asia-Pacific | 10.7% CAGR (2026–2035) | National centralization programs; voluntary donor expansion |
| South America | USD 0.24 Billion (2025) | PAHO procurement frameworks; paid-to-voluntary transition |
| Middle East & Africa | 8.5% CAGR (2026–2035) | PEPFAR-funded HIV screening; cold-chain modernization |
| Total | USD 3.46 Billion (2025) | — |

The Blood Screening Market exhibits a clear geographic hierarchy, with mature markets in North America and Europe accounting for the majority of revenue, while Asia-Pacific's rapid infrastructure build-out positions it as the principal growth engine through 2035.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 78% of regional share | FDA-mandated Babesia and bacterial screening expansion |
| Canada | 14% of regional share | Canadian Blood Services automation upgrade |
| Mexico | USD 0.11 Billion (2025) | COFEPRIS regulatory alignment with FDA standards |

The United States remains the single largest national Blood Screening Market, anchored by the American Red Cross and Vitalant, which collectively process over 13 million donations annually. The 2024 nationwide Babesia screening mandate and the FDA's draft guidance on bacterial testing for platelets have created step-function demand increases for expanded NAT panels. Canada's blood system, centralized under Canadian Blood Services and Héma-Québec, is midway through a CAD 180 Million instrument modernization program expected to conclude by 2028 [[17]](https://blood.ca).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 9.2% CAGR (2026–2035) | Paul-Ehrlich-Institut quality mandates |
| United Kingdom | 22% of regional share | NHSBT pathogen-reduction rollout |
| France | USD 0.19 Billion (2025) | EFS centralized NAT procurement |
| Italy | 8.8% CAGR (2026–2035) | National Blood Centre modernization |
| Spain | USD 0.09 Billion (2025) | Regional blood-center consolidation |
| Nordic Countries | 7% of regional share | Joint Scandinavian procurement tenders |
| Russia | 8.3% CAGR (2026–2035) | Federal blood-service digitization initiative |
| Rest of Europe | USD 0.12 Billion (2025) | EU-funded cross-border blood-safety programs |

The revised EU Blood, Tissues and Cells Regulation (adopted 2025) mandates expanded viral panels including hepatitis E for all member states, creating a synchronized procurement wave across the Blood Screening Market in Europe [[5]](https://europarl.europa.eu). The UK's NHSBT is piloting pathogen-reduction for all platelet concentrates, which is expected to reshape screening-panel economics by allowing selective test de-escalation for PRT-treated components.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 32% of regional share | CNBG centralized procurement and NAT mandate |
| India | 11.8% CAGR (2026–2035) | NBTC voluntary donor expansion and mobile NAT units |
| Japan | USD 0.14 Billion (2025) | Japanese Red Cross Society high-throughput screening |
| South Korea | 10.3% CAGR (2026–2035) | KFDA enhanced quality-control requirements |
| ASEAN | USD 0.08 Billion (2025) | WHO-supported regional screening harmonization |
| Rest of Asia-Pacific | 9.5% CAGR (2026–2035) | Bilateral development bank funding for blood safety |

Asia-Pacific represents the fastest-growing region in the Blood Screening Market, driven by China's mandate that all blood centers with annual collections exceeding 100,000 units adopt NAT by 2026, and India's National Blood Transfusion Council initiative to establish 300 new model blood banks by 2029 [[6]](https://mohfw.gov.in). Japan's mature but highly quality-conscious market continues to invest in advanced automation, with the Japanese Red Cross operating one of the world's most centralized and technology-intensive screening networks.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58% of regional share | ANVISA quality enforcement and Hemobras procurement |
| Argentina | 9.1% CAGR (2026–2035) | Plan Nacional de Sangre modernization |
| Rest of South America | USD 0.04 Billion (2025) | PAHO technical assistance programs |

Brazil dominates the South American Blood Screening Market through Hemobras and a network of public hemocenters that processed approximately 3.6 million donations in 2024. ANVISA's progressive alignment with FDA-equivalent quality standards is driving a transition from rapid tests to NAT for first-time donors, while PAHO procurement agreements are making reagent costs more accessible for smaller Andean and Caribbean blood services.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28% of regional share | Vision 2030 healthcare infrastructure investment |
| UAE | USD 0.03 Billion (2025) | Dubai Health Authority quality accreditation |
| South Africa | 9.0% CAGR (2026–2035) | SANBS and Western Province Blood Service capacity expansion |
| Egypt | 8.7% CAGR (2026–2035) | National Blood Transfusion Services centralization |
| Rest of MEA | USD 0.05 Billion (2025) | PEPFAR and Global Fund screening procurement [18] |

The Middle East & Africa region presents a bifurcated Blood Screening Market: Gulf Cooperation Council states operate sophisticated, well-funded blood centers comparable to European facilities, while sub-Saharan African nations still rely heavily on rapid immunoassays for donor screening. PEPFAR's continued commitment of approximately USD 200 Million annually to HIV testing infrastructure across 15 focus countries sustains baseline demand, and the Global Fund's 2024–2026 allocation cycle includes dedicated transfusion-safety components for the first time [[18]](https://pepfar.gov).

## Competitive Benchmarking

## Competitive Benchmarking

The Blood Screening Market exhibits medium market concentration, with the top five players commanding an estimated 60–68% combined revenue share. The Herfindahl-Hirschman Index (HHI) is estimated at approximately 1,200–1,400, indicating a moderately concentrated competitive structure. Competition centers on closed-system reagent-instrument contracts, regulatory approval breadth, and installed-base lock-in at major blood centers.

| Company | Est. Revenue Share Range | Key Offerings for Blood Screening Market | Strategic Positioning |
| --- | --- | --- | --- |
| Grifols S.A. | ~15–19% | Procleix Panther system; TMA-based NAT assays | Dominant in plasma-center screening; global installed base |
| F. Hoffmann-La Roche AG | ~12–16% | cobas 6800/8800; multiplex NAT panels | High-throughput centralized screening; broad menu |
| Abbott Laboratories | ~10–14% | Alinity s; Architect immunoassay platform | Integrated immunoassay and NAT; emerging-market reach |
| Bio-Rad Laboratories | ~7–10% | IH-500 system; gel-card blood typing | Blood-group typing and immunohematology leader |
| Ortho Clinical Diagnostics | ~5–8% | Ortho Vision analyzer; VITROS immunodiagnostics | Transfusion medicine and blood-bank automation |
| Immucor (Werfen) | ~4–7% | NEO Iris; Echo Lumena; PreciseType HEA | Molecular immunohematology and reference testing |
| Hologic Inc. | ~3–6% | Panther Fusion; Aptima assays | NAT for blood screening through Grifols partnership |
| Quotient Limited | ~2–4% | MosaiQ system; microarray-based typing | Next-gen multiplexed donor testing platform |
| Beckman Coulter (Danaher) | ~2–4% | DxH series; immunoassay analyzers | Hospital-based transfusion screening |
| Siemens Healthineers | ~2–3% | Atellica; ADVIA Centaur immunoassay | Broad diagnostics portfolio; hospital integration |

## Recent News & Developments

## Recent News & Developments

- May 2025: Roche unveiled the Elecsys PRO-C3 test, a quick test that reduces reliance on invasive biopsies by identifying liver fibrosis in 18 minutes.The first human trial of artificial blood based on hemoglobin vesicles, which preserve for two years at room temperature without blood-group matching, started in Japan in March 2025.
- February 2025: The Tina-quant Lp(a) Gen.2 test, the first blood test in the United States to report Lp(a) in molar units, received FDA 510(k) clearance in February 2025.
- January 2025: SpinChip Diagnostics, a portable immunoassay platform that provides whole-blood results in ten minutes, was acquired by bioMérieux.

## Report Scope

## Blood Screening Market Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Global Blood Screening Market covering products, technologies, screening targets, end-users, and regions |
| Study Period | 2021–2035 |
| CAGR (Forecast Period) | 9.0% (2026–2035) |
| Base Year | 2025 — USD 3.46 Billion |
| 2026 Estimate | USD 3.77 Billion |
| 2035 Projection | USD 8.19 Billion |
| Fastest Growing Region | Asia-Pacific (10.7% CAGR) |
| Fastest Growing End-User | Clinical Laboratories (11.0% CAGR) |
| Companies Profiled | 10 (Grifols, Roche, Abbott, Bio-Rad, Ortho Clinical Diagnostics, Immucor, Hologic, Quotient, Beckman Coulter, Siemens Healthineers) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do reagent-rental contracts affect competitive switching for blood centers?**
A: Reagent-rental agreements typically lock blood centers into 5–7-year exclusive supply terms tied to instrument placement. Breaking these contracts early incurs penalties that often exceed 30% of remaining contract value, making mid-cycle vendor switches rare [23].

**Q: What validation requirements apply when a blood center transitions from immunoassay to NAT screening?**
A: Regulatory agencies require parallel testing of 1,000–5,000 donor samples on both old and new platforms before full cutover. This validation phase typically spans 3–6 months and costs USD 150,000–300,000 per analyte [9].

**Q: How does pathogen-reduction technology change the screening panel economics for platelet concentrates?**
A: PRT-treated platelets may qualify for reduced bacterial testing under certain regulatory frameworks. This can lower per-unit screening costs by 10–15%, partially offsetting the USD 20–30 per-unit PRT processing expense [10].

**Q: What role does the Blood Screening Market play in pandemic preparedness infrastructure?**
A: Screening platforms serve as sentinel surveillance networks, detecting emerging pathogens in asymptomatic donors before clinical cases surface. This dual-use capability attracted federal biosurveillance funding exceeding USD 80 Million in the U.S. during 2023–2024 [4].

**Q: How are blood centers in the Blood Screening Market addressing cybersecurity risks in connected screening platforms?**
A: Connected instruments transmitting results to centralized databases face HIPAA and GDPR compliance mandates. Most large centers now require ISO 27001–certified middleware and encrypted data pipelines for all screening-platform integrations [24].

**Q: What procurement strategies optimize per-test costs in the Blood Screening Market for mid-sized blood centers?**
A: Group-purchasing organizations and regional consortia negotiate volume-tiered pricing that can reduce reagent costs by 15–25% versus individual contracts. Joint tenders among 3–5 centers typically reach the volume thresholds needed for tier-one pricing [16].

**Q: How do emerging Babesia and hepatitis E screening requirements expand the addressable Blood Screening Market?**
A: Each new mandated analyte adds USD 2–5 per donation unit in incremental reagent spend. Nationwide Babesia screening alone created an estimated USD 120 Million annual revenue increment in the United States starting in 2024 [2].

**Q: What is the current size of the blood screening market?**
A: The blood screening market reached USD 3.46 billion in 2025 and is projected to reach USD 8.19 billion by 2035.

**Q: What is the CAGR of the blood screening market?**
A: The blood screening market is projected to grow at a CAGR of 9.0% during the forecast period 2026–2035.

**Q: Which region leads the blood screening market?**
A: North America holds the largest share at 38%, while Asia-Pacific is the fastest-growing region at 10.7% CAGR.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/blood-screening-market-6899*